A phase II Clinical Study of CP-4055 as second line therapy in patients with advanced colorectal cancer
Ontology highlight
ABSTRACT: Primary objectives: To evaluate the objective tumour response in patients with advanced colorectal cancer when treated with CP-4055 for infusion D1-5/4w.
Primary endpoints: Tumour response defined as Complete Response (CR) and/or Partial Response (PR), characterized by measuring the target lesions, and according to the RECIST criteria.The Response Rate (= PR + CR) will be estimated and a 95 % confidence interval calculated.
DISEASE(S): A Phase Ii Clinical Study Of Elacyt As Second Line Therapy In Patients With Advanced Colorectal Cancer
PROVIDER: 2521306 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA